rly-4008,fgfr2 inhibitor
cogent biosciences,relay therapeutics
['fgfr2 inhibitor', 'rly-4008']
there's a high unmet need for effective therapies for patients with cholangiocarcinoma w/ fgfr2 alterations. dr. presents data using rly-4008, a potent, highly selective oral fgfr2 inhibitor, to treat patients w/ advanced fgfr2-altered #cholangiocarcinoma. #asco23 
Personalized #CancerTreatment + leading-edge #CancerResearch and #ClinicalTrials = unparalleled #CancerCare. https://t.co/g8MpWrG6ca